Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High- and low-dose radiotherapy with tislelizumab + lenvatinib for unresectable hepatocellular carcinoma
ChiCTR2300074960Phase 4Recruiting
- Sponsor
- Pingxiang People's Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Pingxiang People's Hospital. Primary endpoint: Objective remission rate. Started Sep 2023; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300074960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074960.